ATLANPOLE - Biothérapies

Thinking up tomorrow's medicine

Feeds

News

PhD students, come and take part to the Bio Business Week !

BioBusiness Week 2015

After a successful first edition in 2014 … Save the Date ! The second edition will take place in Angers (France). Attend to a fast track training to create your start up, coached by professionals. Come with your scientific work, leave with a business plan.

CESTI IHU: Unlocking messenger RNA’s potential in order to develop new biotherapeutic products.

The messenger RNA is now considered to be a new generation of natural biotherapeutics, which can use the natural ability of the body to produce its own therapeutic proteins.

Profile of the month : Caroline Le Guiner, at the forefront of research on rare diseases

In 2003, Caroline Le Guiner completed her PhD in Sciences, specializing in genetic and molecular biology particularly in the study of the regulation of alternative splicing. During this work, she was attached to the Cancer Research Institute in Nantes. After years of basic research on the cellular regulation mechanisms, she aspires to use the results of her work in a more concrete way. Thus, her great interest in medicine and patients led her towards applied research. Philippe Moullier, a medical doctor by training, who is also a researcher at INSERM and the founder of Nantes Gene Therapy Laboratory, accepted her in for her post doctorate work. 11 years later, she is still working in the same lab, where she is leading a gene therapy research program, whose goal is to develop drugs to treat a rare disease, Duchenne muscular dystrophy. A first clinical trial is expected to begin within a few months.

Financing: support the development of Carlina Technologies

Logo Carlina Technologies

The company, a member of Atlanpole Biotherapies is actively seeking funding to continue its product development activities.

CESTI IHU and the creation of innovative companies

Through its scientific and medical goals, the CESTI IHU also aims to foster cooperation between academic research and companies, and, with its Atlanpole partner, to promote the emergence of start-up companies by using the results generated by the researchers involved in the program.

MELSORT: a new therapeutic strategy for metastatic melanoma

MELSORT, sustained by the “IGO” LABEX research program aims at using adoptive transfer of melanoma specific T cells selected through an original technology for the treatment of metastatic melanoma. A phase I/II clinical trial based on this therapy has been validated by the French authorities and will begin in Nantes in June 2015 including 17 patients with metastatic melanoma.

Effimune obtains regulatory approval for Phase I clinical trial in humans of its new immunomodulator FR104

Logo Effimune

[press release] Effimune announced that it had received the authorization from the Belgian regulatory authority, the FAMHP (Federal Agency for Medicines and Health Products) for a Phase I clinical trial of FR104, its drug candidate for controlling the regulation of the immune system. This double-blind randomized clinical trial will take place on 70 healthy volunteers (both men and women) over a period of 9 months, and will prepare the future development of FR104 in rheumatoid arthritis and kidney transplantation.

Your news

Events

15 june : International Cancer Cluster Showcase

Bio International Convention

Alongside BIO 2015, come and meet the companies members of our cluster experts in oncology during this event. Participation is free, sign up now to attend your place.

29th June - 10th July : Research Summer Schools in Angers

Research Summer Schools Angers

Research, Cancer, Ethics Bioinformatics, Plant science Mitochondrial medicine... Share your knowledge with international researchers and students from different countries and cultures.

16 - 18 sept. : CMSB 2015 in Nantes

CMSB 2015

The CMSB 2015 conference will be held in Nantes from Sept. 16th to Sept. 18th. The conference brings together computer scientists, biologists, mathematicians, engineers and physicists interested in a system-level understanding of biological processes.

Our events

The Atlanpole Biotherapies competitive cluster combines the expertise of laboratories, companies and technical departments for a public-private offer of services, comprehensive, relevant and competitive, in the value chain of bio-medicine from target discovery to clinical evaluation

 

Our ambition is to become a reference center on an international scale for the development of diagnostic and therapeutic solutions in the field of biotherapies.
Atlanpole Biotherapies is a competitive cluster certified by the Ministry of Industry (July 2005). 

Atlanpole UK

Annuaire